News & Announcements

NF2 Research and Media News 2009

NF2 Research News Clin Cancer Res, PubMed, Consensus recommendations to accelerate clinical trials for Neurofibromatosis type 2 The New England Journal of Medicine, “Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2”, Plotkin SR, et al. NF2 Clinical Trials: Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors ClinicalTrials.gov… Continue Reading →

NF2 Research and Media News 2008

Data from INSERM provide new insights into gene therapy … is the product of a tumor suppressor gene mutated in neurofibromatosis type 2 (NF2). Although the consequences of NF2 mutations on Schwann cell proliferation are well … Studies from University of California have provided new information about gene therapy …  “Neurofibromatosis type 2 (NF2) is… Continue Reading →

AdvocureNF2 Consumer Participation for FY08 CDMRP NFRP

Scientific Peer Review of Neurofibromatosis Research Applications for the Department of Defense For Immediate Release. Neurofibromatosis advocate Rosemary Lee recently participated in the evaluation of research proposals submitted to the Neurofibromatosis Research Program (NFRP) sponsored by the U.S. Department of Defense. Rosemary Lee was nominated for participation in the program by Advocure NF2, Inc (http://www.advocurenf2.org/).… Continue Reading →

A Prospective Natural History Study of Patients with Neurofibromatosis Type 2 (NF2)

This study will examine over the long-term the progress of patients with neurofibromatosis Type 2 (NF2), a condition associated with tumors of the nerves, brain and spinal cord. It will study patients tumors to learn how fast they can grow and if certain factors might affect their growth. It will also examine the effects of… Continue Reading →

NF2 Research News, 2007

Announcement from CTF.org: The NF Preclinical Consortium (NFPC) is a multi-site collaboration of six research Centers for Phase 1 (2007-2011). Each is focused on different tumor manifestations of NF1 and NF2. The two NF2 centers are: Harvard Med School/Mass General Hospital, Director: Andrea McClatchey, Ph.D. House Ear Institute, Director: Marco Giovannini, MD, Ph.D. Tumor Focus… Continue Reading →